Drug Profile
NMRA 511
Alternative Names: BTRX-323511; NMRA-511Latest Information Update: 12 Oct 2021
Price :
$50
*
At a glance
- Originator BlackThorn Therapeutics
- Developer Neumora Therapeutics
- Class Anxiolytics; Small molecules
- Mechanism of Action Vasopressin 1a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anxiety disorders
Most Recent Events
- 12 Oct 2021 BlackThorn Therapeutics has been acquired and merged into Neumora Therapeutics
- 12 Oct 2021 Phase-I clinical trials in Anxiety disorders in USA (unspecified route) before October 2021 (Neumora Therapeutics pipeline, October 2021)
- 07 Oct 2021 Neumora Therapeutics acquires BlackThorn Therapeutics